You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Harvard Business School

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 9,441,046

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,441,046
Title:Methods for increasing forced expiratory volume in asthmatics using benralizumab
Abstract: Provided herein is are methods of increasing forced expiratory volume in one second (FEV.sub.1) in an asthma patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.
Inventor(s): Ward; Christine (Gaithersburg, MD), Roskos; Lorin (Gaithersburg, MD), Wang; Bing (Gaithersburg, MD), Raible; Donald (Berwyn, PA)
Assignee: ASTRAZENECA AB (Sodertalje, SE)
Application Number:14/454,138
Patent Claims:see list of patent claims

Details for Patent 9,441,046

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Astrazeneca Ab FASENRA benralizumab INJECTABLE;INJECTION 761070 001 2017-11-14   Start Trial ASTRAZENECA AB (Sodertalje, SE) 2033-08-12 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.